echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Yunnan will still develop vaccine-focused biotech drugs in the next five years

    Yunnan will still develop vaccine-focused biotech drugs in the next five years

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the biotechnology drug industry focusing on vaccines has become the fastest growing field in the biopharmaceutical industry in Yunnan Province
    .
    The recently released "14th Five-Year Plan for the Innovation and Development of the Biomedical Industry in Yunnan Province" clarifies that the vaccine biotechnology drug industry will remain a key development area in Yunnan Province in the next five years
    .
     
    In the next five years, Yunnan Province will still need to work hard to improve the upstream and downstream industrial chains, enhance the research and development capabilities of new vaccines, accelerate the construction of a rapid response system for major infectious diseases, strengthen frontier basic research, and enrich product pipelines
    .
     
    Relying on Kunming and Yuxi to build biotech drug industry bases focusing on vaccines, vigorously develop new biological vaccines, antibody drugs, biosimilar drugs, cell preparations, blood products such as albumin, coagulation factors, immunoglobulins, and other proteins, Research and development and production of new products of polypeptide and nucleic acid drugs
    .
     
    Yunnan Province also encourages vaccine companies to build digital and intelligent production lines and improve the level of production technology
    .
    Guide enterprises in the province to establish, acquire and merge R&D institutions at home and abroad, build a quality system, R&D system and production technology system in line with international standards, promote the international registration and WHO pre-certification of biological vaccine products, and build vaccine production that meets international quality standards Supply base and domestic leading monoclonal antibody drug industry base, increase open cooperation with South Asia, Southeast Asia and the Indian Ocean Rim, and develop markets in South Asia, Southeast Asia, Africa and Europe and the United States
    .
    (Finish)
    In recent years, the biotechnology drug industry focusing on vaccines has become the fastest growing field in the biopharmaceutical industry in Yunnan Province
    .
    The recently released "14th Five-Year Plan for the Innovation and Development of the Biomedical Industry in Yunnan Province" clarifies that the vaccine biotechnology drug industry will remain a key development area in Yunnan Province in the next five years
    .
     
    In the next five years, Yunnan Province will still need to work hard to improve the upstream and downstream industrial chains, enhance the research and development capabilities of new vaccines, accelerate the construction of a rapid response system for major infectious diseases, strengthen frontier basic research, and enrich product pipelines
    .
     
    Relying on Kunming and Yuxi to build biotech drug industry bases focusing on vaccines, vigorously develop new biological vaccines, antibody drugs, biosimilar drugs, cell preparations, blood products such as albumin, coagulation factors, immunoglobulins, and other proteins, Research and development and production of new products of polypeptide and nucleic acid drugs
    .
     
    Yunnan Province also encourages vaccine companies to build digital and intelligent production lines and improve the level of production technology
    .
    Guide enterprises in the province to establish, acquire and merge R&D institutions at home and abroad, build a quality system, R&D system and production technology system in line with international standards, promote the international registration and WHO pre-certification of biological vaccine products, and build vaccine production that meets international quality standards Supply base and domestic leading monoclonal antibody drug industry base, increase open cooperation with South Asia, Southeast Asia and the Indian Ocean Rim, and develop markets in South Asia, Southeast Asia, Africa and Europe and the United States
    .
    (Finish)
      In recent years, the biotechnology drug industry focusing on vaccines has become the fastest growing field in the biopharmaceutical industry in Yunnan Province
    .
    The recently released "14th Five-Year Plan for the Innovation and Development of the Biomedical Industry in Yunnan Province" clarifies that the vaccine biotechnology drug industry will remain a key development area in Yunnan Province in the next five years
    .
     
      In the next five years, Yunnan Province will still need to work hard to improve the upstream and downstream industrial chains, enhance the research and development capabilities of new vaccines, accelerate the construction of a rapid response system for major infectious diseases, strengthen frontier basic research, and enrich product pipelines
    .
     
      Relying on Kunming and Yuxi to build biotech drug industry bases focusing on vaccines, vigorously develop new biological vaccines, antibody drugs, biosimilar drugs, cell preparations, blood products such as albumin, coagulation factors, immunoglobulins, and other proteins, Research and development and production of new products of polypeptide and nucleic acid drugs
    .
     
      Yunnan Province also encourages vaccine companies to build digital and intelligent production lines and improve the level of production technology
    .
    Guide enterprises in the province to establish, acquire and merge R&D institutions at home and abroad, build a quality system, R&D system and production technology system in line with international standards, promote the international registration and WHO pre-certification of biological vaccine products, and build vaccine production that meets international quality standards Supply base and domestic leading monoclonal antibody drug industry base, increase open cooperation with South Asia, Southeast Asia and the Indian Ocean Rim, and develop markets in South Asia, Southeast Asia, Africa and Europe and the United States
    .
    (Finish)
    Enterprise Enterprise Standard Standard Standard_
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.